CN101732287B - 甘露醇甘油注射液及其制备方法 - Google Patents
甘露醇甘油注射液及其制备方法 Download PDFInfo
- Publication number
- CN101732287B CN101732287B CN200910243431XA CN200910243431A CN101732287B CN 101732287 B CN101732287 B CN 101732287B CN 200910243431X A CN200910243431X A CN 200910243431XA CN 200910243431 A CN200910243431 A CN 200910243431A CN 101732287 B CN101732287 B CN 101732287B
- Authority
- CN
- China
- Prior art keywords
- injection
- glycerol
- water
- mannite
- mannitol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 title claims abstract description 281
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 title claims abstract description 86
- 235000010355 mannitol Nutrition 0.000 title claims abstract description 85
- 238000002347 injection Methods 0.000 title claims abstract description 52
- 239000007924 injection Substances 0.000 title claims abstract description 52
- 238000002360 preparation method Methods 0.000 title claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 51
- 239000008215 water for injection Substances 0.000 claims abstract description 49
- 238000007917 intracranial administration Methods 0.000 claims abstract description 22
- 238000000034 method Methods 0.000 claims abstract description 14
- 206010022773 Intracranial pressure increased Diseases 0.000 claims abstract description 9
- 201000009941 intracranial hypertension Diseases 0.000 claims abstract description 9
- 238000011049 filling Methods 0.000 claims abstract description 8
- 238000001914 filtration Methods 0.000 claims abstract description 8
- 230000001154 acute effect Effects 0.000 claims abstract description 5
- 239000003814 drug Substances 0.000 claims abstract description 5
- 206010061218 Inflammation Diseases 0.000 claims abstract description 4
- 230000001684 chronic effect Effects 0.000 claims abstract description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 4
- 230000004054 inflammatory process Effects 0.000 claims abstract description 4
- 208000014674 injury Diseases 0.000 claims abstract description 4
- 208000018389 neoplasm of cerebral hemisphere Diseases 0.000 claims abstract description 4
- 229930195725 Mannitol Natural products 0.000 claims description 45
- 239000000594 mannitol Substances 0.000 claims description 45
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 9
- 230000002490 cerebral effect Effects 0.000 claims description 7
- 238000007789 sealing Methods 0.000 claims description 7
- 230000001954 sterilising effect Effects 0.000 claims description 7
- 230000008733 trauma Effects 0.000 claims description 3
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 208000009304 Acute Kidney Injury Diseases 0.000 abstract description 7
- 208000033626 Renal failure acute Diseases 0.000 abstract description 7
- 201000011040 acute kidney failure Diseases 0.000 abstract description 7
- 208000012998 acute renal failure Diseases 0.000 abstract description 7
- 210000003734 kidney Anatomy 0.000 abstract description 6
- 210000004556 brain Anatomy 0.000 abstract description 5
- 206010021143 Hypoxia Diseases 0.000 abstract description 4
- 239000003795 chemical substances by application Substances 0.000 abstract description 4
- 230000037149 energy metabolism Effects 0.000 abstract description 4
- 210000002216 heart Anatomy 0.000 abstract description 4
- 230000008859 change Effects 0.000 abstract description 3
- 230000008569 process Effects 0.000 abstract description 3
- 239000013078 crystal Substances 0.000 abstract description 2
- 201000010099 disease Diseases 0.000 abstract description 2
- 208000003906 hydrocephalus Diseases 0.000 abstract 2
- 208000030886 Traumatic Brain injury Diseases 0.000 abstract 1
- 208000027418 Wounds and injury Diseases 0.000 abstract 1
- 230000006907 apoptotic process Effects 0.000 abstract 1
- 208000026106 cerebrovascular disease Diseases 0.000 abstract 1
- 230000006378 damage Effects 0.000 abstract 1
- 230000034994 death Effects 0.000 abstract 1
- 230000014759 maintenance of location Effects 0.000 abstract 1
- 230000027939 micturition Effects 0.000 abstract 1
- 210000003061 neural cell Anatomy 0.000 abstract 1
- 230000001737 promoting effect Effects 0.000 abstract 1
- 210000001835 viscera Anatomy 0.000 abstract 1
- 235000011187 glycerol Nutrition 0.000 description 70
- 229940090044 injection Drugs 0.000 description 36
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 239000007788 liquid Substances 0.000 description 9
- 238000002425 crystallisation Methods 0.000 description 8
- 230000008025 crystallization Effects 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 239000005715 Fructose Substances 0.000 description 7
- 229930091371 Fructose Natural products 0.000 description 7
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 7
- 229940080526 mannitol injection Drugs 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 206010002660 Anoxia Diseases 0.000 description 3
- 241000976983 Anoxia Species 0.000 description 3
- 206010048962 Brain oedema Diseases 0.000 description 3
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 3
- 239000000006 Nitroglycerin Substances 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000007953 anoxia Effects 0.000 description 3
- 208000006752 brain edema Diseases 0.000 description 3
- 229960003711 glyceryl trinitrate Drugs 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- 208000002403 Encephalocele Diseases 0.000 description 2
- 206010018910 Haemolysis Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 206010061481 Renal injury Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 238000005660 chlorination reaction Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000008588 hemolysis Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 208000037806 kidney injury Diseases 0.000 description 2
- 230000009223 neuronal apoptosis Effects 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- -1 triglyceride compound Chemical class 0.000 description 2
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 206010009192 Circulatory collapse Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010014418 Electrolyte imbalance Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010025476 Malabsorption Diseases 0.000 description 1
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 206010043994 Tonic convulsion Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000008084 cerebral blood perfusion Effects 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 210000002532 foramen magnum Anatomy 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000002706 hydrostatic effect Effects 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000007694 nephrotoxicity Effects 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 206010040560 shock Diseases 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 208000029257 vision disease Diseases 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Images
Landscapes
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200910243431XA CN101732287B (zh) | 2009-12-23 | 2009-12-23 | 甘露醇甘油注射液及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200910243431XA CN101732287B (zh) | 2009-12-23 | 2009-12-23 | 甘露醇甘油注射液及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101732287A CN101732287A (zh) | 2010-06-16 |
CN101732287B true CN101732287B (zh) | 2012-05-30 |
Family
ID=42456661
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200910243431XA Expired - Fee Related CN101732287B (zh) | 2009-12-23 | 2009-12-23 | 甘露醇甘油注射液及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101732287B (zh) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103432066A (zh) * | 2013-07-23 | 2013-12-11 | 蚌埠丰原涂山制药有限公司 | 一种复方甘露醇注射液及其制备方法 |
CN104027305B (zh) * | 2014-06-04 | 2015-04-08 | 回音必集团(江西)东亚制药有限公司 | 甘露醇注射液 |
CN105147600B (zh) * | 2015-10-23 | 2018-06-29 | 广西裕源药业有限公司 | 一种复方甘露醇注射液 |
CN105147602B (zh) * | 2015-10-23 | 2018-06-29 | 广西裕源药业有限公司 | 甘露醇注射液 |
CN105287368B (zh) * | 2015-10-23 | 2018-06-29 | 广西裕源药业有限公司 | 一种甘露醇注射液 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1256919A (zh) * | 1999-12-03 | 2000-06-21 | 刘慧光 | 双甘注射液及其制备方法 |
CN1562047A (zh) * | 2004-03-25 | 2005-01-12 | 杨喜鸿 | 甘油转化糖注射液 |
CN1698625A (zh) * | 2005-06-09 | 2005-11-23 | 刘晓曼 | 一种“甘油果糖”复合原料药的配比和制备方法 |
-
2009
- 2009-12-23 CN CN200910243431XA patent/CN101732287B/zh not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1256919A (zh) * | 1999-12-03 | 2000-06-21 | 刘慧光 | 双甘注射液及其制备方法 |
CN1562047A (zh) * | 2004-03-25 | 2005-01-12 | 杨喜鸿 | 甘油转化糖注射液 |
CN1698625A (zh) * | 2005-06-09 | 2005-11-23 | 刘晓曼 | 一种“甘油果糖”复合原料药的配比和制备方法 |
Non-Patent Citations (1)
Title |
---|
杨章群等.双甘注射液的实验研究及临床疗效观察.《河北职工医学院学报》.2000,第17卷(第1期),第18-20页. * |
Also Published As
Publication number | Publication date |
---|---|
CN101732287A (zh) | 2010-06-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Marcelis et al. | Spontaneous low cerebrospinal fluid pressure headache | |
CN101732287B (zh) | 甘露醇甘油注射液及其制备方法 | |
CN101991589B (zh) | 一种甘油果糖注射液及其制备方法 | |
CN104473938B (zh) | 一种治疗慢性心衰药物及其制备方法 | |
Yang et al. | Successful treatment of severe lactic acidosis caused by a suicide attempt with a metformin overdose | |
CN102228617B (zh) | 一种治疗失眠的药物组合物 | |
CN103054883B (zh) | 一种含有果糖二磷酸钠化合物的药物组合物 | |
CN1332660C (zh) | 一种止血药卡络磺钠注射液及其制备方法 | |
Chowdhury et al. | Acute hemodynamic disturbances during lumbar spine surgery | |
CN102639128B (zh) | 用于预防糖尿病的磺酰胺 | |
CN105147602B (zh) | 甘露醇注射液 | |
CN105287368B (zh) | 一种甘露醇注射液 | |
CN104027305B (zh) | 甘露醇注射液 | |
CN101836997B (zh) | 一种甘油与果糖组合物的制备方法 | |
CN113952297B (zh) | 一种注射用含地加瑞克的药物组合物及其制备方法和应用 | |
CN105147600B (zh) | 一种复方甘露醇注射液 | |
CN105663034A (zh) | 米力农药物组合物及其制备方法 | |
CN101626771B (zh) | 梅尼埃病治疗药 | |
US20170360827A1 (en) | Pharmaceutical Use of Potassium Hydroxide | |
CN102488696A (zh) | 一种甘油果糖组合物注射液及其制备方法 | |
CN102008554B (zh) | 一种治疗上消化道出血的中药混合物 | |
CN105311040A (zh) | 一种含有果糖二磷酸钠的用于治疗循环系统疾病的新药物组合物针剂 | |
CN106551901A (zh) | 兽用复方甘露醇注射液 | |
CN102247338A (zh) | 一种甘油与果糖组合物 | |
CN102274194A (zh) | 一种含托烷司琼化合物的药物组合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20180720 Address after: 100023 No. 41, Lao Jun Tang Village, Chaoyang District, Beijing. Co-patentee after: Zhang Lu Patentee after: BEIJING SHENGFANG DALONG MEDICAL TECHNOLOGY DEVELOPMENT Co.,Ltd. Co-patentee after: Liu Haibo Address before: 100023 No. 41, Lao Jun Tang Village, Chaoyang District, Beijing. Co-patentee before: Zhang Lu Patentee before: BEIJING SHENGFANG DALONG MEDICAL TECHNOLOGY DEVELOPMENT Co.,Ltd. Co-patentee before: Hou Xiangqian |
|
TR01 | Transfer of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120530 |
|
CF01 | Termination of patent right due to non-payment of annual fee |